Meiragtx Holdings (MGTX)
NASDAQ:MGTX
Want to see MGTX full AI Analyst Report?
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:62Neutral
Price Target:
$12.00
▲(18.58% Upside)
Action:Reiterated
Date:06/19/26
The score is held back primarily by weak financial performance (large ongoing losses and negative equity), partially offset by strong technical momentum and a set of positive corporate events (funding, partnerships, and program/regulatory progress). Valuation contributes only modestly because the negative P/E reflects continued unprofitability and no dividend yield is available.
Positive Factors
High Gross Margin & Improving OCF
A ~94% gross margin indicates highly valuable revenue streams and strong unit economics that sustain long-term profitability potential. The shift to positive operating cash flow (~$8M TTM) reduces near-term liquidity pressure and shows the business can begin converting revenue into operating cash, improving structural financing flexibility as programs advance.
Negative Factors
Large Ongoing Net Losses
A ~ $121M TTM net loss versus ~$80M revenue shows the business has not yet scaled to cover its cost base; persistent negative margins require sustained external funding or rapid commercial success to reach sustainable profitability, creating ongoing execution and financing risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin & Improving OCF
A ~94% gross margin indicates highly valuable revenue streams and strong unit economics that sustain long-term profitability potential. The shift to positive operating cash flow (~$8M TTM) reduces near-term liquidity pressure and shows the business can begin converting revenue into operating cash, improving structural financing flexibility as programs advance.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)741.77K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth131.13%
EPS Growth35.61%
CountryUS
Employees375
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume626,619
30 Day Avg. Volume741,775
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue12.29
Enterprise Value/Gross Profit13.41
Enterprise Value/Ebitda-10.24
Forecast
1Y Price Target
$24.00Price Target Upside137.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$49.29M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.76M | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Gross Profit | 73.09M | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| EBITDA | -95.72M | -89.40M | -121.69M | -57.05M | -116.07M | -71.40M |
| Net Income | -120.53M | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
Balance Sheet | ||||||
| Total Assets | 244.66M | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M |
| Cash, Cash Equivalents and Short-Term Investments | 71.54M | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total Debt | 87.53M | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Total Liabilities | 302.79M | 250.22M | 201.92M | 188.57M | 200.50M | 134.76M |
| Stockholders Equity | -58.13M | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
Cash Flow | ||||||
| Free Cash Flow | -2.34M | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
| Operating Cash Flow | 8.28M | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Investing Cash Flow | -4.66M | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Financing Cash Flow | 446.00K | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
Meiragtx Holdings Technical Analysis
Positive
10.12
Price Trends
9.70
Positive
8.73
Positive
8.41
Positive
Market Momentum
0.20
Negative
69.04
Neutral
80.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 10.12 is above the 20-day moving average (MA) of 9.68, above the 50-day MA of 9.70, and above the 200-day MA of 8.41, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 69.04 is Neutral, neither overbought nor oversold. The STOCH value of 80.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 78 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.05B | -7.64 | 474.91% | ― | 131.13% | 35.61% | |
56 Neutral | $1.84B | -18.12 | -56.07% | ― | 3.42% | -11.04% | |
52 Neutral | $504.99M | -4.09 | -36.83% | ― | 383560.87% | 20.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $4.25B | -15.02 | -77.01% | ― | ― | -49.51% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
11.32
4.98
78.55%
TSHA
Taysha Gene Therapies
6.42
3.96
160.98%
FDMT
4D Molecular Therapeutics
9.66
5.53
133.90%
ERAS
Erasca
13.67
12.30
897.81%
Meiragtx Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
MeiraGTx Shareholders Back Board Slate and Auditor Renewal
Positive
Jun 15, 2026
On June 11, 2026, MeiraGTx Holdings plc held its annual general meeting of shareholders, with about 81.4% of outstanding ordinary shares represented. Shareholders elected three Class II directors, Ellen Hukkelhoven, Ph.D., Nicole Seligman, and Deb...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
MeiraGTx Forms Strategic Gene Therapy Collaboration with Hologen
Positive
Apr 24, 2026
On April 20, 2026, MeiraGTx Holdings and affiliates completed the initial closing of a strategic collaboration with Guernsey-based Hologen Limited to jointly research, develop, manufacture and commercialize MeiraGTx’s AAV-GAD and AAV-BDNF ge...
Business Operations and StrategyPrivate Placements and Financing
MeiraGTx Announces Public Equity Offering to Fund Growth
Positive
Apr 16, 2026
On April 16, 2026, MeiraGTx Holdings plc entered into an underwriting agreement with BofA Securities, Inc. and Goldman Sachs Co. LLC for a public offering of 11,111,111 ordinary shares at $9.00 per share, with all shares sold by the company. The ...
Business Operations and StrategyPrivate Placements and Financing
MeiraGTx Reacquires Bota-Vec Rights, Advances XLRP Program
Positive
Apr 16, 2026
On April 15, 2026, MeiraGTx reacquired from Janssen all rights and related intellectual property to botaretigene sparoparvovec (bota-vec), an AAV-RPGR gene therapy for X-linked retinitis pigmentosa, for $25 million upfront plus potential milestone...
Business Operations and StrategyProduct-Related Announcements
MeiraGTx Reports Durable Phase 1 AQUAx Gene Therapy Data
Positive
Apr 16, 2026
On April 16, 2026, MeiraGTx reported three-year follow-up data from its Phase 1 AQUAx trial of AAV-hAQP1 in patients with grade 2/3 late radiation-induced xerostomia, showing the one-time gene therapy remained safe and well tolerated with no dose-...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances
Positive
Mar 26, 2026
On March 25, 2026, MeiraGTx amended its notes purchase and warrant agreements with Perceptive Credit Holdings, extending note maturity to May 2, 2027, committing to redeem $25 million of principal by June 30, 2026, and cutting the warrant exercise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.